ONTXW
Income statement / Annual
Last year (2020), Onconova Therapeutics Inc. Warrants's total revenue was $231,000.00,
a decrease of 89.42% from the previous year.
In 2020, Onconova Therapeutics Inc. Warrants's net income was -$25.16 M.
See Onconova Therapeutics Inc. Warrants,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
| Operating Revenue |
$231,000.00
|
$2.18 M
|
$1.23 M
|
$787,000.00
|
$5.55 M
|
$11.46 M
|
$800,000.00
|
$4.75 M
|
$46.19 M
|
$1.49 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$231,000.00 |
$2.18 M |
$1.23 M |
$787,000.00 |
$5.55 M |
$11.46 M |
$800,000.00 |
$4.75 M |
$46.19 M |
$1.49 M |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$16.90 M
|
$15.54 M
|
$16.92 M
|
$19.12 M
|
$20.07 M
|
$25.90 M
|
$49.43 M
|
$50.18 M
|
$52.76 M
|
$22.62 M
|
| General & Administrative
Expenses |
$8.33 M
|
$8.35 M
|
$7.59 M
|
$7.41 M
|
$0.00
|
$9.53 M
|
$15.12 M
|
$16.79 M
|
$0.00
|
$6.44 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$8.33 M
|
$8.35 M
|
$7.59 M
|
$7.41 M
|
$0.00
|
$9.53 M
|
$15.12 M
|
$16.79 M
|
$0.00
|
$6.44 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$9.18 M |
$0.00 |
$0.00 |
$0.00 |
$15.71 M |
$0.00 |
| Operating Expenses |
$25.22 M |
$23.88 M |
$24.51 M |
$26.52 M |
$29.25 M |
$35.43 M |
$64.54 M |
$66.98 M |
$68.47 M |
$29.06 M |
| Cost And Expenses |
$25.22 M |
$23.88 M |
$24.51 M |
$26.52 M |
$29.25 M |
$35.43 M |
$64.54 M |
$66.98 M |
$68.47 M |
$29.06 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2,000.00 |
$4,000.00 |
$8.61 M |
$19,000.00 |
| Depreciation &
Amortization |
$13,000.00
|
$14,000.00
|
$55,000.00
|
$88,000.00
|
$96,000.00
|
$150,000.00
|
$434,000.00
|
$446,000.00
|
$319,000.00
|
$316,000.00
|
| EBITDA |
-$25.14 M
|
-$21.48 M
|
-$20.64 M
|
-$23.99 M
|
-$19.56 M
|
-$23.81 M
|
-$63.23 M
|
-$61.66 M
|
-$20.99 M
|
-$25.96 M
|
| EBITDA Ratio |
-108.83 |
-9.84 |
-16.81 |
-30.48 |
-3.53 |
-2.08 |
-79.03 |
-12.97 |
-0.45 |
-17.46 |
| Operating Income Ratio
|
-108.19
|
-9.94
|
-18.96
|
-32.7
|
-4.27
|
-2.09
|
-79.68
|
-13.09
|
-0.48
|
-18.54
|
| Total Other
Income/Expenses Net |
-$160,000.00
|
$206,000.00
|
$2.75 M
|
$1.66 M
|
$4.05 M
|
-$35,000.00
|
-$32,000.00
|
$101,000.00
|
-$7.63 M
|
$1.28 M
|
| Income Before Tax |
-$25.15 M |
-$21.49 M |
-$20.53 M |
-$24.08 M |
-$19.65 M |
-$24.01 M |
-$63.78 M |
-$62.12 M |
-$29.91 M |
-$26.29 M |
| Income Before Tax Ratio
|
-108.89
|
-9.85
|
-16.72
|
-30.6
|
-3.54
|
-2.1
|
-79.72
|
-13.07
|
-0.65
|
-17.68
|
| Income Tax Expense |
$4,000.00 |
$10,000.00 |
-$124,000.00 |
$13,000.00 |
$14,000.00 |
$16,000.00 |
$19,000.00 |
$435,000.00 |
$975,000.00 |
$1.30 M |
| Net Income |
-$25.16 M |
-$21.50 M |
-$20.57 M |
-$24.09 M |
-$19.67 M |
-$23.98 M |
-$63.68 M |
-$62.54 M |
-$29.91 M |
-$26.29 M |
| Net Income Ratio |
-108.9 |
-9.85 |
-16.75 |
-30.61 |
-3.55 |
-2.09 |
-79.6 |
-13.16 |
-0.65 |
-17.68 |
| EPS |
-0.14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS Diluted |
-0.14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Weighted Average Shares
Out |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares
Out Diluted |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
